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in Adolescent and Adult Patients with High-Risk T Cell
Acute Lymphoblastic Leukemia
Mohammad Bakr,1 Walid Rasheed,1 Said Y. Mohamed,1 Fahad Al-Mohareb,1
Naeem Chaudhri,1 Fahad Al-Sharif,1 Hazza Al-Zahrani,1 Ghuzayel Al-Dawsari,1
Abu Jafar Saleh,1 Amr Nassar,1 Shad Ahmed,1 Assem Elghazaly,1
Syed O. Ahmed,1 Khalid Ibrahim,1 Wahiba Chebbo,1 Ghada M. El Gohary,1
Muhamad H. Al Mahayni,1 Fazal Hussain,1 Zubeir Nurgat,2
Tusneem Ahmed Elhassan,3 Claudia U. Walter,4 Mahmoud Aljurf1Allogeneic hematopoietic stem cell transplantation (allo-SCT) is often recommended for patients with T cell
acute lymphoblastic leukemia (T-ALL) in second or later complete remission ($CR2) and sometimes in
high-risk (HR) patients in first complete remission (CR1). Between January 1995 and July 2009, 53 patients
with HR T-ALL underwent allo-SCT at our institution. Median age was 18 years (range, 14-51). Thirty-two
patients (60.3%) were in CR1, 18 (34%) were in$CR2, and 3 (5.7%) were in relapse. The cumulative incidence
of nonrelapse mortality at 5 years was 22.5%. The cumulative incidence of grade II-IV acute graft-versus-host
disease (GVHD) was 40.2%, and that of chronic GVHD was 43.7%. The majority of relapses (88.9%) occurred
within 1 year after SCT. The cumulative incidence of relapse (CIR) at 5 years was 35.6%. CIR was 29.8% in
patients in CR1, 35.3% in patients in $CR2 and all patients transplanted in relapse had disease recurrence
post-allo-SCT (P 5 .000). Overall survival (OS) and disease-free survival (DFS) at 5 years were 43.5% and
41.8%, respectively. The 5-year OS was 53.5% (95% CI 34.5%-72.5%) and 5-year DFS was 52% (95% CI
33%-71%) in patients who underwent allo-SCT in CR1, compared with 31.9% (95% CI, 9%-54.8%) and
29.4% (95%CI 7.6%-51.2%) in thosewho underwent allo-SCT in$CR2.Onmultivariate analysis, disease status
at SCTremained significantly associated withOS (P5.007), DFS (P5.002), and CIR (P5.000). The presence of
extramedullary disease at diagnosis had no effect on the different outcomes. Grade II-IV acute GVHDwas sig-
nificantly associated with a lowerOS (P5.006) andDFS (P5.01). Our data indicate that allo-SCTrepresents an
effective treatment for HRT-ALL, particularly when performed in CR1.
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T cell acute lymphoblastic leukemia (T-ALL)
accounts for approximately 20%-25% of cases of acute
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tures that are distinct from those of B cell acute lym-
phoblastic leukemia (B-ALL) [2,3]. In recent study,
better outcomes were associated with the use of more
intensive treatment, and T-ALL was associated with
greater 5-year overall survival (OS) compared with
B-ALL (48% versus 41%; P 5 .001) [4]. Nonetheless,
long-term outcomes in adult patients with T-ALL
remain unsatisfactory, with a 5-year OS of only
30%-50% [4-6]. Furthermore, outcomes in patients
who relapse is very poor, with a 5-year OS of 5% [7].
Although allogeneic hematopoietic stem cell trans-
plantation (allo-SCT) is usually recommended for
adult patients in second or later complete remission
($CR2), it also has been offered as postremission ther-
apy for some patients in first CR (CR1), especially
those with high-risk (HR) features [8]. The most1897
Table 1. Patient Characteristics
Value
All patients, n 53
Patient age, years, median (range) 18 (14-51)
Age group, years, n (%)
14 to #20 36 (68)
>20 to #35 14 (26.4)
>35 3 (5.6)
Patient sex, male/female, n 46/7
Donor age, years, median (range) 21 (3-54)
Donor sex, male/female, n 27/26
Donor–recipient sex match
Male–male 23 (43.4)
Male–female 4 (7.5)
Female–female 3 (5.7)
Female–male 23 (43.4)
T cell subtypes
1898 Biol Blood Marrow Transplant 18:1897-1904, 2012M. Bakr et al.widely cited HR factors include age, WBC count, im-
munophenotype, cytogenetics, time to CR, extrame-
dullary disease, and more recently, minimal residual
disease (MRD) [9-12].
Data on outcomes of allo-SCT in patients with
HR T-ALL are limited. To assess outcomes in this
group of patients and to define factors predictive of
outcome after allo-SCT, we analyzed our prospec-
tively collected data on adult patients with T-ALL
who underwent allo-SCT between 1995 and 2009.
To our knowledge, this is one of the largest single in-
stitutional studies reported to date describing the out-
come and predictive factors after allo-SCT in patients
with HR T-ALL.Pro-T cell 1 (1.9)
Pre-T cell 21 (39.6)
Cortical T cell 15 (28.3)
Mature T cell 10 (18.9)
Unknown 6 (11.3)
WBC  109/L at diagnosis, median (range) 97 (0.17-712)
Extramedullary disease at diagnosis
CNS 6 (11.3)
Mediastinum 19 (35.8)
Other 14 (26.4)
Cytogenetics
Intermediate 22 (41.5)
HR/VHR 6 (11.3)
ND 25 (47.2)
Disease status at transplantation
CR1 32 (60.3)
$CR2 18 (34)
Relapse 3 (5.7)
Time from diagnosis to transplantation,
months, median (range)
CR1 3.9 (3-10)
>CR1 14 (5-50)
Conditioning regimen
Cyclophosphamide/TBI 50 (94.3)
Busulfan/cyclophosphamide 2 (3.8)
Fludarabine/TBI 1 (1.9)
GVHD prophylaxis
MTX/CSA 51 (96.2)
MTX/CSA/steroid 1 (1.9)
CSA/Mycophenolate mofetil 1 (1.9)
CD 34+ stem cells infused,  106/kg body
weight, median (range)
PB 4.6 (2.6-7.9)
BM 3.7 (1.6-7.9)
Stem cell source
PB 15 (28.3)
BM 37 (69.8)
Cord blood 1 (1.9)
ND indicates no data.PATIENTS AND METHODS
Patient and Disease Characteristics
We analyzed the outcomes of adults (age $14
years) withT-ALLwho received a full-intensity condi-
tioning regimen and underwent allo-SCT at King
Faisal Specialist Hospital and Research Center
between January 1995 and July 2009. Treatment pro-
tocols were approved by the hospital’s Institutional
Review Board, and written informed consent was ob-
tained from all patients and donors. Patients eligible
for allo-SCT includedHR patients in CR1 and any pa-
tient in $CR2 or relapse. Patients in CR1 had one or
more of the following HR features: age $35 years,
WBC count at presentation $100,000/mm3, residual
disease in bone marrow (BM) at day 14 postinduction,
central nervous system (CNS) involvement at diagno-
sis, HR cytogenetic features, and the need for more
than one induction regimen to achieve CR1. T cell
subtype was determined according to the classification
scheme of the European Group for Immunological
Classification of Leukemias [13], and myeloid markers
were defined as the coexpression of CD13 and/or
CD33. Cytogenetic studies were performed on
unstimulated BM or peripheral blood (PB) cultures
according to standard protocols. Karyotypes were
risk-classified as proposed by the Southwest Oncology
Group’s 9400 study [14]. (Detailed information about
our institutional ALL protocol is available at http://
www.kfshrc.edu.sa/hem_malignancies.)Transplantation Procedure and Supportive Care
Patient and donor characteristics are summarized in
Table 1. Full-intensity conditioning regimens were
used for all patients. The probability of having an
HLA-matched sibling donor in our population is 68%
[15]. Although our center protocol dictates the search
for a matched unrelated donor (MUD) in patients
with acute leukemia who need allo-SCT and do not
have a related donor, the likelihood of finding a MUDfrom international donor registries is low because of
the differences inHLAhaplotype frequency in theMid-
dle East region [16]. Fifty-two transplants were from an
HLA-matched sibling donors and only 1 transplant was
from HLA-matched unrelated cord blood, given that
the patient had neither an HLA-matched sibling donor
nor a MUD. The majority of patients (94.3%) received
cyclophosphamide 60 mg/kg once daily i.v. for 2 con-
secutive days (total dose, 120 mg/kg), followed by 12
Gy of fractionated total body irradiation (TBI) given
in 6 fractions. Partial lung shielding was established
by the patient’s arm. Two patients (3.8%) received
Biol Blood Marrow Transplant 18:1897-1904, 2012 1899Allogeneic SCT in Adult High-Risk T-ALLbusulfan 16 mg/kg (1 mg/kg per dose orally every 6
hours over 4 consecutive days) and cyclophosphamide
60 mg/kg once daily i.v. for 2 consecutive days (total
dose, 120 mg/kg). One patient (1.9%) received fludara-
bine 30 mg/m2 of body surface area/day i.v. for 5 days
and 12 Gy fractionated TBI given in 6 fractions. Che-
motherapy doses of conditioning regimens were based
on adjusted body weight.
Short-course methotrexate plus cyclosporine
(MTX/CSA) was the most common GVHD prophy-
laxis regimen used, given to 51 patients (96.2%).
MTX was given in a dose of 15 mg/m2 body surface
area i.v. on day 1 and 10 mg/m2 on days 3 and 6. All
patients received 3 doses of MTX. CSA was started
on the day before transplantation and was given i.v.
at a dose of 1.5 mg/kg every 12 hours up to day 21.
Thereafter, the patients received oral cyclosporine
5 mg/kg every 12 hours. The full dose of cyclosporine
was given up to day 50 posttransplantation, with a tar-
get level of 200-400 ug/L. CSA was tapered in accor-
dance with our institutional protocol.
All patients received irradiated and filtered blood
products. RBC transfusions were given to patients
with a hemoglobin level\80 mg/dL. Platelet transfu-
sions were given to patients with a platelet count\10
 109/L, or\15 109/L in those with fever or clinical
signs of bleeding. Granulocyte colony-stimulating
factor was not administered routinely but was given
to selected neutropenic patients with infective compli-
cations at the discretion of the treating physician;
overall 14 patients (26.4%) received granulocyte
colony-stimulating factor. All patients underwent cy-
tomegalovirus (CMV) surveillance with weekly pe-
ripheral blood PP65 antigenemia testing during
hospitalization. CMV antigenemia monitoring con-
tinued at every clinic visit up to day 120 posttransplan-
tation in all patients and sometimes longer for patients
who continued with immunosuppressive therapy for
GVHD. Antimicrobial prophylaxis against viral her-
pes and Pneumocystis jiroveci infections continued for
6 months after discontinuation of immunosuppressive
therapy. Antifungal prophylaxis was used up to day 30,
and longer in patients with GVHD receiving immuno-
suppressive therapy. Detailed information on our in-
stitutional SCT protocol is available at http://
www.kfshrc.edu.sa/HSCT.Engraftment and Toxicities
The time to neutrophil engraftment was defined as
the first of 3 consecutive days with an absolute neutro-
phil count (ANC) of$0.5 109/L.The time of platelet
engraftmentwas defined as thefirst dayof 3 consecutive
days with a sustained untransfused platelet count of
$20  109/L. Toxicity after SCT was graded acc-
ording to the National Cancer Institute’s Common
Toxicity Criteria (NCI, Bethesda, MD, USA).Acute and Chronic GVHD
Acute GVHD (aGVHD) was diagnosed and
scored as grade 0-IV in accordance with standard mor-
phologic, clinical, and biochemical criteria [17].
Chronic GVHD (cGVHD) was assessed in patients
surviving more than 100 days after allo-SCT.
Statistical Analysis
The probabilities of OS and DFS were estimated
using the Kaplan-Meier method [18], and survival
curves were compared using the log-rank test. Relapse,
nonrelapse mortality (NRM), aGVHD, and cGVHD
were determined with cumulative incidence estimates,
with death in remission, relapse, and death without
GVHD as competing risk events [19]. The Fine-
Gray method [20] was used for group comparisons.
Outcomes evaluated in univariate analysis included
death, NRM, relapse, and DFS. Factors evaluated
for association with these outcomes are listed in
Table S1 (available at http://dx.doi.org/10.1016/j.bbmt.
2012.07.011). Cox regression models were used to ex-
amine the association of various factors with OS and
DFS [21]. The impact of aGVHD or cGVHD on out-
come was evaluated by introducing GVHD as a time-
dependent covariate. Cox regression models were also
used to evaluate the association of various factors with
NRM and cumulative incidence of relapse (CIR). This
was done with proper censoring, with relapse censored
in the NRM and death in remission censored in the
CIR. Potential prognostic factors were considered for
multivariate analysis if the P value in univariate analysis
was#.20. Multivariate regression models were fit using
stepwise regression, with entry and exit P values of .10.
Statistical analyses were performed using SPSS version
17.0 (SPSS, Inc., Chicago, IL) and R version 2.10.0
with software packages survival version 2.35-7 and
cmprsk version 2.2-1 (http://www.r-project.org).RESULTS
Patient Features
Patient characteristics are summarized in Table 1.
Between January 1995 and July 2009, 118 of the 463
patients with newly diagnosed ALL referred to our
center were diagnosed with T-ALL. Fifty-three pa-
tients underwent allo-SCT and were included in this
study; some of them were referred in CR for allo-
SCT after undergoing induction chemotherapy out-
side our institution. The median patient age was
18 years (range, 14-51 years). At the time of allo-
SCT, 32 patients (60.3%) were in CR1, 18 (34%)
were in $CR2, and 3 (5.7%) were in relapse. T cell
subtypes are shown in Table 1. Nine patients (17%)
had myeloid marker coexpression. Twenty-eight pa-
tients (52.8%) had successful metaphase karyotyping,
Table 2. Results
Value
All patients 53
ANC recovery, days, median (range)* 21 (11-47)
Platelet recovery, days, median (range)* 16 (9-125)
aGVHD grade, n (%)
Grade 0-I 32 (60.4)
Grade II 6 (11.3)
Grade III-IV 15 (28.3)
Day of aGVHD onset, median (range) 31 (4-100)
cGVHD, n (%) 15 (28.3)
Infection, n (%)
Febrile neutropenia 48 (90.6)
Fungal infection 4 (7.5)
CMV infection 22 (41.5)
Herpes zoster 12 (22.6)
Hepatic sinusoidal obstruction syndrome 7 (13.2)
Hemorrhagic cystitis 3 (5.7)
Pulmonary complications, n (%)
IPS 8 (15.1)
BOOP 5 (9.4)
Hemorrhage 1 (1.9)
Relapse (n 5 18)
Day of relapse, median (range) 167 (49-426)
Survival, n (%)
Alive 26 (49.1)
Dead 27 (50.9)
NRM at day l00 6 (11.3)
Causes of death (n 5 27), n (%)
Relapse 16 (59.3)
IPS/ARDS 3 (11.1)
Lung fibrosis/BOOP 3 (11.1)
aGVHD 1 (3.7)
Infection 2 (7.4)
Other 2 (7.4)
ARDS indicates adult respiratory distress syndrome; BOOP, bronchioli-
tis obliterans with organizing pneumonia; HZ, herpes zoster; IPS, idio-
pathic pneumonia syndrome.
*Engraftment data were available for 48 patients.
1900 Biol Blood Marrow Transplant 18:1897-1904, 2012M. Bakr et al.18 of whom also underwent fluorescence in situ
hybridization analysis. Karyotype data were not avail-
able for 25 patients (47.2%); some patients demon-
strated insufficient metaphases, whereas others were
referred for allo-SCT in CR without sufficient cytoge-
netic data at diagnosis. Twenty-two patients (41.5%)
had intermediate-risk cytogenetic features (13 in
CR1, 8 in $CR2, and 1 in relapse), including 10 pa-
tients (19%) with normal karyotype. Six patients
(11.3%) had HR or very HR (VHR) cytogenetic fea-
tures (3 in CR1 and 3 in $CR2), including 4 patients
with complex cytogenetics, 1 patient with MLL gene
rearrangement, and 1 patient with t(4;11). None of
our patients exhibited Philadelphia chromosome or
BCR-ABL1 fusion (Table S2) available at http://
dx.doi.org/10.1016/j.bbmt.2012.07.011.
Engraftment
Engraftment data were available for 48 of the
53 patients. One patient died on day 65 posttransplan-
tation without achieving engraftment, and data are
missing for 4 patients. All the patients survived for
more than 21 days posttransplantation. ANC and
platelet engraftment data are presented in Table 2.
The median time to neutrophil recovery was 18 days
in the PB group (range, 12-32 days) and 22 days in
the BM group (range, 11-47 days) (P 5 .10), and the
median time to platelet recovery was 14 days in the
PB group (range, 9-28 days) and 19 days in the BM
group (range, 11-125 days) (P 5 .07).
Transplantation-Related Toxicity
The cumulative incidence of NRM for all 53 pa-
tients was 11.6% (95% CI, 10.4%-12.8%) at day 100
post-SCT and 22.5% (95% CI, 20.9%-24.1%) at 5
years post-SCT. Nonrelapse causes of death are sum-
marized in Table 2. NRM at 5 years was not signifi-
cantly different between patients in CR1 and those in
$CR2 (17% [95% CI, 16.8%-17.2%] versus 31.8%
[95% CI, 29.1%-34.5%]; P 5 .20). Transplantation-
related toxicities are summarized in Table 2.
aGVHD and cGVHD
The cumulative incidence of grade II-IV aGVHD
was 40.2% (95% CI, 38.3%-42.1%), and that of
cGVHD (both limited and extensive) was 43.7%
(95% CI, 41.1%-46.3%). The median time to onset
of cGVHD was 166 days (range, 100-778 days).
Relapse
Eighteen patients relapsed, at a median time of
167 days (range, 49-426 days) after SCT. The CIR at
5 years was 35.6% (95% CI, 34%-38%). Sixteen
patients (88.9%) relapsed less than 1 year post-SCT,
with the latest relapse occurring at 1.2 years. The CIR
at 5 years was significantly associated with disease statusat the timeof transplantation.TheCIRwas 29.8%(95%
CI, 28.4%-31.2%) in patientswho underwent allo-SCT
in CR1 and 35.3% (95% CI, 33%.3-37.3%) in those
who underwent allo-SCT in $CR2; all patients who
underwent allo-SCT while in relapse experienced dis-
ease recurrence less than 3 months posttransplantation
(P 5 .000). CIR was 83.3% (95% CI, 77.8%-88.7%)
in patients with HR/VHR cytogenetic features, com-
pared with 27.3% (95% CI, 24.7%-29.9%) in patients
with intermediate-risk cytogenetic features (P 5 .03)
(Figure 1).Survival and Causes of Death
At the time of this report, 26 of our 53 patients
were still alive, 2 with relapse. Causes of death are sum-
marized in Table 2. For all 53 patients, the 5-year
OS was 43.5% (95% CI, 30%-57%), and the 5-year
DFS was 41.8% (95% CI, 29%-56%). Both OS and
DFS were significantly related to disease status at the
time of allo-SCT. Five-year OS was 53.5% (95% CI,
34.5%-72.5%) and DFS was 52% (95% CI, 33%-
71%) in patients who underwent allo-SCT in CR1,
compared with 31.9% (95% CI, 9%-54.8%) and
29.4% (95% CI, 7.6%-51.2%) for those who
Figure 1. CIR by cytogenetics.
Figure 3. DFS by disease status at transplantation.
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both) (Figures 2 and 3).
Five-year OS was 59.5% (95% CI, 34%-85%) in
CD1a1 patients versus 38.9% (95% CI, 20%-57%)
in CD1a2 patients (P 5 .416). Five-year DFS was
53.3% (95% CI, 28%-78%) versus 37.8% (95% CI,
20%-56%) (P 5 .648).
There were no significant differences in OS or
DFS between patients with intermediate-risk cytoge-
netic features and those with HR/VHR cytogenetic
features (OS, 45% versus 16.7%, P 5 .32; DFS,
39.8% versus 16.7%, P 5 .26).
Prognostic Factors
Univariate analysis
Results of the univariate analysis are shown
in Table S1 available at (http://dx.doi.org/10.1016/
j.bbmt.2012.07.011). All outcome endpoints were sig-Figure 2. OS by disease status at transplantation.nificantly related to disease status at allo-SCT. OS and
DFS were lower in patients who underwent allo-SCT
in $CR2 compared with those who underwent allo-
SCT in CR1. In addition, patients who underwent
allo-SCT in $CR2 had a higher relapse rate and
a trend toward higher NRM. Female-to-female trans-
plantation was associated with a lower DFS and
a higher relapse rate compared with male-to-male
transplantation. The relapse rate was higher in patients
with HR/VHR cytogenetic features at the time of di-
agnosis compared with those with intermediate-risk
features. Extramedullary disease or CNS involvement
at diagnosis had no effect on OS, DFS, relapse rate, or
NRM. Grade II-IV aGVHD was significantly associ-
ated with lowerOS, lower DFS, and a 5.6-fold increase
in NRM compared with grade 0-I aGVHD. aGVHD
was not associated with lower relapse rate. Although
cGVHD was numerically associated with a lower
relapse rate, this association was not statistically signif-
icant (HR, .38; 95% CI, .09-1.59; P 5 .19).
Multivariate analysis
Table 3 shows the results of the multivariate anal-
ysis. Disease status at allo-SCT remained statistically
significantly associated with OS, DFS, and CIR. OS
and DFS were lower in patients who underwent allo-
SCTwhile in relapse compared with those who under-
went allo-SCT in CR1 (OS: HR, 15.4; 95% CI,
2.8-85.3; P 5 .002; DFS: HR, 27.7; 95% CI, 4.3-
179.7; P 5 .000).
Grade II-IV aGVHD modeled as a time-
dependent covariate was significantly associated with
lower OS and DFS compared with grade 0-I aGVHD.
There was no significant difference in relapse rate be-
tween patients who developed cGVHD and those
without cGVHD (HR, 0.87; 95% CI, 0.74-1.03;
Table 3. Multivariate Analysis
Endpoint/Covariate Hazard Ratio 95% CI P Value
Death
aGVHD II-IV* 1.19 1.05-1.35 .006
Disease status at transplantation .007
CR1 1.00
$CR2 1.3 0.47-4.10 .60
Relapse 15.40 2.80-85.30 .002
NRM
aGVHD II-IV* 1.68 0.77-3.65 .18
Relapse
Disease status at transplantation .00
CR1 1.00
$CR2 1.90 0.60-5.40 .20
Relapse 111.70 10.60-1170.50 .00
Cytogenetics .001
Intermediate 1.00
ND 0.75 0.20-2.40 .60
HR/VHR 8.80 2.20-34.00 .02
cGVHD* 0.87 0.74-1.03 .10
Disease-free survival
aGVHD II-IV* 1.20 1.04-1.40 .01
Disease status at transplantation .002
CR1 1.00
$CR2 1.60 0.61-4.12 .33
Relapse 27.70 4.30-179.70 .00
ND indicates no data.
*Time-dependent modeling.
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at the time of diagnosis had an 8.8-fold higher relapse
rate compared with those with intermediate-risk fea-
tures (HR, 8.8; 95% CI, 2.2-34; P 5 .02).DISCUSSION
Survival appears to be similar or possibly more fa-
vorable in patients with T-ALL compared with those
with B-ALL [6]; however, the literature is deficient
on prospective studies focusing on T-ALL, owing to
the disorder’s relative rarity. Many previous prospec-
tive ALL trials have reported the outcomes of T cell
subtypes as part of subgroup analysis. This makes pre-
cise comparison of outcomes in different studies quite
difficult, because of differences in patient characteris-
tics and treatment protocols. Allo-SCT is usually rec-
ommended for patients with HR ALL in CR1 and
those who relapse and achieve CR2 [22]. According
to our institutional protocol, allo-SCT is offered to
adults (age $14 years) with T-ALL at HR of relapse;
thus, our uniformly treated patients represent HR
group, including those with allo-SCT in CR1.
In general, a 5-year OS of 30%-50% has been re-
ported in adult patients with T-ALL [6]. In our series,
the OS for these HR patients was 43.5% for the whole
group and 53.5% for those who underwent allo-SCT
in CR1. One of the largest series of adult ALL to
date is the UKALLXII/ECOG 2993 trial. Marks
et al. [23] reported descriptions and outcomes of a large
cohort of adults with T-ALL treated in this prospec-
tive trial with ‘‘biological assignment.’’ Of note, thedonor group in this study included patients with and
without HR features, with a median age of 29 years,
compared with 18 years in our study. Five-year OS
was 61% for the donor group, compared with 46%
for those without an available donor (P5 .02). For pa-
tients with ALL in CR1, allo-SCT incurred a survival
advantage compared with autologous SCT or chemo-
therapy [24]. The benefit was greater in the standard-
risk patients compared with the HR patients. This
result was clearly seen in the UKALLXII/ECOG
2993 trial [25], as well as in a recent meta-analysis of
11 donor/no-donor studies [26]. However, this obser-
vation is limited by the donor versus no-donor assign-
ment in these studies. This lack of survival difference
between the donor and no-donor patients in the HR
group was related to the high NRM in these HR pa-
tients. The assumption that all patients with ALL in
CR1 are candidates for allo-SCT is not yet supported
by the results of prospective randomized trials.
Relapse rates after allo-SCT are much lower than
those after chemotherapy or autologous SCT, but
allo-SCT is associated with higher NRM [25]. In our
study, the relapse rate at 5 years was 35.6%, compared
with 25% for patients with T-ALL with donors in the
UKALLXII/ECOG 2993 study. This difference might
be explained by the fact that all of our patients wereHR,
including those in CR1. Our 5-year NRM of 22.5% is
comparable to the 22% NRM in the T-ALL donor
group in the UKALLXII/ECOG 2993 study.
Although our patients were all HR and thus would be
expected to have a higher NRM, this similar rate might
be explained by the fact that most of our patients are
young, with a median age of 18 years.
Cytogenetics is considered probably the singlemost
important prognostic factor in adult patients with ALL.
Patients with T-ALL with a complex karyotype have
poor survival (19% at 5 years) [23]. In our study, OS in
patients withHR/VHRcytogenetic features was similar
to that reported in the UKALLXII/ECOG 2993 trial.
There were no statistically significant differences in
OS and DFS between patients with intermediate-risk
cytogenics and those with HR/VHR cytogenetics, pos-
sibly because of the relatively small size of our cohort.
Furthermore, all of our patients with intermediate-risk
cytogenetics had other HR features.
The incidence of grade III-IV aGVHD in our
study cohort was 28%, compared with the roughly
20% reported in the literature [27]. We have no clear
explanation for this difference, but our sample size is
too small to allow a ready comparison with other stud-
ies reporting aGVHD incidence. Allo-SCT in this
group of patients was mainly from female to male,
which may be a factor in this increased incidence.
Although in the present study cGVHD appeared
to be associated with a relative reduction in relapse
rate, this was not statistically significant. In contrast,
aGVHD was not associated with a lower relapse rate,
Biol Blood Marrow Transplant 18:1897-1904, 2012 1903Allogeneic SCT in Adult High-Risk T-ALLprobably owing to its association with increased risk of
early death. The efficacy of allo-SCT in ALL is medi-
ated in part by the graft-versus-leukemia effect [28].
The suggested GVHD-associated graft-versus-leuke-
mia effect of allo-SCT in ALL is indicated by the lower
relapse rate in patients with aGVHD and/or cGVHD.
The magnitude of this antileukemic effect of GVHD
was similar in T-ALL and B-ALL [29].
Interestingly, in our study cohort, patients with
CNS or other extramedullary disease at diagnosis
had better OS and DFS. All of these patients under-
went allo-SCT in CR1, which turned out to be the
most important predictive factor for outcome after
allo-SCT. In the UKALLXII/ECOG 2993 trial,
CNS disease at diagnosis did not affect outcomes in
patients with T-ALL, although it did affect outcomes
in the complete patient cohort [23]. Lazarus et al.
[30] reported that allo-SCT can confer long-term
DFS in patients with ALL and CNS involvement at
diagnosis. In a study from the Fred Hutchinson
Cancer Center, extramedullary disease at time of di-
agnosis was found to have no effect on outcome after
allo-SCT [31].
Many previous studies have shown that allo-SCT
is beneficial for adults with HR ALL in CR1 [26].
Recent advances in molecular genetics and genomics
allow better identification of HR patients [32,33].
The recent incorporation of molecular MRD analysis
in clinical studies has clear implications for
redefining the prognosis of ALL [34].
Several novel purine analogs, including clofara-
bine [35] and nelarabine, have shown promise in the
treatment of ALL. Nelarabine has demonstrated re-
markable activity in relapsed/refractory T-ALL and
currently is being evaluated in first-line studies by
at least 3 groups (M.D. Anderson Cancer Center,
GMALL, and MRC-ECOG) [36]. Other novel
agents also have been investigated and proposed for
integration in the management of ALL, including
mammalian target of rapamycin inhibitors, sonic
hedgehog antagonists, and gamma-secretase inhibi-
tors [37-39].
In summary, allo-SCT can provide effective treat-
ment for HR patients with T-ALL, particularly if per-
formed in CR1. Outcomes of allo-SCT in patients
beyond CR1 appear to be significantly less favorable.
Future clinical studies should focus on better risk strat-
ification using recent molecular MRD applications,
along with standard clinical and cytogenetic predictors
of outcome, to identify more patients in CR1 status
who might benefit from allo-SCT.ACKNOWLEDGMENTS
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